Professor Suzhan Zhang, MD
Director, Cancer Institute
Zhejiang University Multidisciplinary Diagnosis and Treatment Center for Colorectal Cancer
Zhejiang University School of Medicine
Hangzhou, China
Director, Cancer Institute
Zhejiang University Multidisciplinary Diagnosis and Treatment Center for Colorectal Cancer
Zhejiang University School of Medicine
Hangzhou, China
Related Videos
What sources are used, and should be used in China, to determine what targeted, anti-cancer therapies should be deployed in genomic alterations detected by NGS sequencing? “Broad molecular profiling” is already recommended for 1st line ...
What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE?
In what important ways does NGS and CGP address the fundamental changes that systemic cancer treatment is undergoing toward the use of molecularly targeted drugs prescribed to patients across multiple tumor types?
For which solid tumors do you find NGS genomic profiling to be most valuable for identifying molecular drivers that can reliably guide the use of targeted therapy?